(InSilico Medicine, Inc.) Johns Hopkins scientists invent multifunctional antibody-ligand traps (Y-traps), a new class of cancer immunotherapeutics. They develop Y-traps comprising an antibody targeting an immune checkpoint (CTLA-4 or PD-L1) fused to a TGFβ trap. In humanized mouse models, these Y-traps reverse immune suppression and inhibit growth of tumors that do not respond to current immune checkpoint inhibitors.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2HDlnSR
No comments:
Post a Comment